Jesãºs Cienfuegos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jesãºs Cienfuegos has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Mario Alonso-Vanegas
Department of Neurosurgery, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
4 shared publications - Sandra Orozco-Suárez
Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, “Dr. Bernardo Sepúlveda”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México 06720, CP, Mexico
3 shared publications A. Nani
Department of Genetics, National Institute of Psychiatry "Ramón de la Fuente Muñiz" (INPRFM), Mexico City, Mexico
2 shared publications- Bárbara Nettel-Rueda
Department of Neurosurgery, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Mexico City, Mexico
2 shared publications - Carlos Sabas Cruz Fuentes
Instituto Nacional de Psiquiatría, Ramón de la Fuente Muñiz, Av. Xochimilco #101. Col. San Lorenzo, Huipulco, Tlalpan, Mexico City 14370, Mexico
2 shared publications - Daniel San-Juan
Epilepsy Clinic, National Institute of Neurology and Neurosurgery
2 shared publications
Latest Publications
- Open Access
Utility of gene tumor expression of VEGF, FOXM1*3 and CD-133 on diagnosis and prognosis of brain gliomas
Objective: This paper seeks to quantify the normalized expression of transcripts FOXM1*3, VEGF, CD133 , and MGMT and their relation with the histopathological and molecular diagnosis and with the probability of estimating tumor progression-free survival of gliomas. Methods: A cohort of patients was made up of patients aged over 18 years with a histological and molecular diagnosis of gliomas from the year 2011 to 2018. The patients had a complete tumor resection. Patients with high-grade glioma received adjuvant management (temozolamide and radiotherapy). Clinical and imaging follow-up was carried out periodically to identify the time of progression free survival (PFS). Results: Ninety-one patients (age range, 18–85 years) comprised the study cohort with a predominance of males. The expression of FOXM1*3, VEGF , and CD133 allowed the differentiation of astrocytomas grade II from GBM. ROC curves proved statistically significant in the GBM model ( p < 0.05), demonstrating greatest sensitivity with FOXM1*3 (91%), and greatest specificity with VEGF (93%). The age-adjusted Cox multivariate model established that a PFS 50% of 25 months corresponds to a median value of 5.3 for VEGF and 0.42 for CD133. Conclusions: The normalized expression of transcripts FOXM1 *3, VEGF , and CD133 allow us to estimate the probability of PFS, especially in gliomas grades II and IV; likewise, their overexpression defines the diagnosis of GBM. Authorship: Substantial contributions to conception and design (IAFR, BNR, MARF, GG, IG), acquisition of data (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CRA), analysis and interpretation of data (IAFR, BNR, MARF, JCM, SOS, CEN, HMG, IG). Drafting the article (IAFR, BNR, MARF, IFE, LCP, SOS, JAC, IG), revising it critically for important intellectual content (IAFR, JCM, CEN, GG, HMG, CRA, IG) Final approval of the version to be published (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CEN, GG, HMG, CRA, IG).
Open AccessUtility of gene tumor expression of VEGF, FOXM1*3 and CD-133 on diagnosis and prognosis of brain gliomas
Objective: This paper seeks to quantify the normalized expression of transcripts FOXM1*3, VEGF, CD133 , and MGMT and their relation with the histopathological and molecular diagnosis and with the probability of estimating tumor progression-free survival of gliomas. Methods: A cohort of patients was made up of patients aged over 18 years with a histological and molecular diagnosis of gliomas from the year 2011 to 2018. The patients had a complete tumor resection. Patients with high-grade glioma received adjuvant management (temozolamide and radiotherapy). Clinical and imaging follow-up was carried out periodically to identify the time of progression free survival (PFS). Results: Ninety-one patients (age range, 18–85 years) comprised the study cohort with a predominance of males. The expression of FOXM1*3, VEGF , and CD133 allowed the differentiation of astrocytomas grade II from GBM. ROC curves proved statistically significant in the GBM model ( p < 0.05), demonstrating greatest sensitivity with FOXM1*3 (91%), and greatest specificity with VEGF (93%). The age-adjusted Cox multivariate model established that a PFS 50% of 25 months corresponds to a median value of 5.3 for VEGF and 0.42 for CD133. Conclusions: The normalized expression of transcripts FOXM1 *3, VEGF , and CD133 allow us to estimate the probability of PFS, especially in gliomas grades II and IV; likewise, their overexpression defines the diagnosis of GBM. Authorship: Substantial contributions to conception and design (IAFR, BNR, MARF, GG, IG), acquisition of data (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CRA), analysis and interpretation of data (IAFR, BNR, MARF, JCM, SOS, CEN, HMG, IG). Drafting the article (IAFR, BNR, MARF, IFE, LCP, SOS, JAC, IG), revising it critically for important intellectual content (IAFR, JCM, CEN, GG, HMG, CRA, IG) Final approval of the version to be published (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CEN, GG, HMG, CRA, IG).
- 1 December 2018
- Published by Elsevier in Epilepsy Research
- Vol. 148, 37-43
Overexpression of inflammatory-related and nitric oxide synthase genes in olfactory bulbs from frontal lobe epilepsy patients
- 1 December 2018
- Published by Elsevier in Epilepsy Research
- Vol. 148, 37-43
Overexpression of inflammatory-related and nitric oxide synthase genes in olfactory bulbs from frontal lobe epilepsy patients
- 19 May 2017
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (5) , 1-11
Increased Expression of Brain-Derived Neurotrophic Factor Transcripts I and VI, cAMP Response Element Binding, and Glucocorticoid Receptor in the Cortex of Patients with Temporal Lobe Epilepsy
A body of evidence supports a relevant role of brain-derived neurotrophic factor (BDNF) in temporal lobe epilepsy (TLE). Magnetic resonance data reveal that the cerebral atrophy extends to regions that are functionally and anatomically connected with the hippocampus, especially the temporal cortex. We previously reported an increased expression of BDNF messenger for the exon VI in the hippocampus of temporal lobe epilepsy patients compared to an autopsy control group. Altered levels of this particular transcript were also associated with pre-surgical use of certain psychotropic. We extended here our analysis of transcripts I, II, IV, and VI to the temporal cortex since this cerebral region holds intrinsic communication with the hippocampus and is structurally affected in patients with TLE. We also assayed the cyclic adenosine monophosphate response element-binding (CREB) and glucocorticoid receptor (GR) genes as there is experimental evidence of changes in their expression associated with BDNF and epilepsy. TLE and pre-surgical pharmacological treatment were considered as the primary clinical independent variables. Transcripts BDNF I and BDNF VI increased in the temporal cortex of patients with pharmacoresistant TLE. The expression of CREB and GR expression follow the same direction. Pre-surgical use of selective serotonin reuptake inhibitors, carbamazepine (CBZ) and valproate (VPA), was associated with the differential expression of specific BDNF transcripts and CREB and GR genes. These changes could have functional implication in the plasticity mechanisms related to temporal lobe epilepsy.
- 19 May 2017
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (5) , 1-11
Increased Expression of Brain-Derived Neurotrophic Factor Transcripts I and VI, cAMP Response Element Binding, and Glucocorticoid Receptor in the Cortex of Patients with Temporal Lobe Epilepsy
A body of evidence supports a relevant role of brain-derived neurotrophic factor (BDNF) in temporal lobe epilepsy (TLE). Magnetic resonance data reveal that the cerebral atrophy extends to regions that are functionally and anatomically connected with the hippocampus, especially the temporal cortex. We previously reported an increased expression of BDNF messenger for the exon VI in the hippocampus of temporal lobe epilepsy patients compared to an autopsy control group. Altered levels of this particular transcript were also associated with pre-surgical use of certain psychotropic. We extended here our analysis of transcripts I, II, IV, and VI to the temporal cortex since this cerebral region holds intrinsic communication with the hippocampus and is structurally affected in patients with TLE. We also assayed the cyclic adenosine monophosphate response element-binding (CREB) and glucocorticoid receptor (GR) genes as there is experimental evidence of changes in their expression associated with BDNF and epilepsy. TLE and pre-surgical pharmacological treatment were considered as the primary clinical independent variables. Transcripts BDNF I and BDNF VI increased in the temporal cortex of patients with pharmacoresistant TLE. The expression of CREB and GR expression follow the same direction. Pre-surgical use of selective serotonin reuptake inhibitors, carbamazepine (CBZ) and valproate (VPA), was associated with the differential expression of specific BDNF transcripts and CREB and GR genes. These changes could have functional implication in the plasticity mechanisms related to temporal lobe epilepsy.
- 1 February 2016
- Published by Elsevier in Neuroscience
- Vol. 314, 12-21
Increased expression of BDNF transcript with exon VI in hippocampi of patients with pharmaco-resistant temporal lobe epilepsy
- 1 February 2016
- Published by Elsevier in Neuroscience
- Vol. 314, 12-21
Increased expression of BDNF transcript with exon VI in hippocampi of patients with pharmaco-resistant temporal lobe epilepsy
- Open Access
- 5 January 2015
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 8, 442
GABAergic Alterations in Neocortex of Patients with Pharmacoresistant Temporal Lobe Epilepsy Can Explain the Comorbidity of Anxiety and Depression: The Potential Impact of Clinical Factors
Temporal lobe epilepsy (TLE) is a chronic neurodegenerative disease with a high prevalence of psychiatric disorders. Temporal neocortex contributes to either seizure propagation or generation in TLE, a situation that has been associated with alterations of the γ-aminobutyric acid (GABA) system. On the other hand, an impaired neurotransmission mediated by GABA in temporal neocortex has also been involved with the pathophysiology of psychiatric disorders. In spite of these situations, the role of the necortical GABA system in the comorbidity of TLE and mood disorders has not been investigated. The present study was designed to identify alterations in the GABA system such as: binding to GABAA and GABAB receptors and benzodiazepine site, the tissue content of GABA and the expression of the mRNA encoding the α1-6, β1-3 and γ GABAA subunits, in the temporal neocortex of surgically treated patients with TLE with and without anxiety and/or depression. Neocortex of patients with TLE and comorbid anxiety and/or depression showed increased expression of the mRNA encoding the γ2-subunit, reduced GABAB-induced G protein activation in spite of elevated GABAB binding, and lower tissue content of GABA when compared to autopsy controls. Some of these changes significantly correlated with seizure frequency and duration of epilepsy. The results obtained suggest a dysfunction of the GABAergic neurotransmission in temporal neocortex of patients with TLE and comorbid anxiety and/or depression that could be also influenced by clinical factors such as seizure frequency and duration of illness.
- 5 January 2015
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 8, 442
Open AccessGABAergic Alterations in Neocortex of Patients with Pharmacoresistant Temporal Lobe Epilepsy Can Explain the Comorbidity of Anxiety and Depression: The Potential Impact of Clinical Factors
Temporal lobe epilepsy (TLE) is a chronic neurodegenerative disease with a high prevalence of psychiatric disorders. Temporal neocortex contributes to either seizure propagation or generation in TLE, a situation that has been associated with alterations of the γ-aminobutyric acid (GABA) system. On the other hand, an impaired neurotransmission mediated by GABA in temporal neocortex has also been involved with the pathophysiology of psychiatric disorders. In spite of these situations, the role of the necortical GABA system in the comorbidity of TLE and mood disorders has not been investigated. The present study was designed to identify alterations in the GABA system such as: binding to GABAA and GABAB receptors and benzodiazepine site, the tissue content of GABA and the expression of the mRNA encoding the α1-6, β1-3 and γ GABAA subunits, in the temporal neocortex of surgically treated patients with TLE with and without anxiety and/or depression. Neocortex of patients with TLE and comorbid anxiety and/or depression showed increased expression of the mRNA encoding the γ2-subunit, reduced GABAB-induced G protein activation in spite of elevated GABAB binding, and lower tissue content of GABA when compared to autopsy controls. Some of these changes significantly correlated with seizure frequency and duration of epilepsy. The results obtained suggest a dysfunction of the GABAergic neurotransmission in temporal neocortex of patients with TLE and comorbid anxiety and/or depression that could be also influenced by clinical factors such as seizure frequency and duration of illness.